These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19774378)

  • 1. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
    Lukka PB; Paxton JW; Kestell P; Baguley BC
    Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).
    Lukka PB; Kestell P; Paxton JW; Baguley BC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Nov; 875(2):368-72. PubMed ID: 18926778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
    Lukka PB; Paxton JW; Kestell P; Baguley BC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):151-60. PubMed ID: 22660735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.
    Lukka PB; Chen YY; Finlay GJ; Joseph WR; Richardson E; Paxton JW; Baguley BC
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1013-22. PubMed ID: 24036845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.
    Lukka PB; Paxton JW; Atwell GJ; Kestell P; Baguley BC
    J Pharm Biomed Anal; 2012 Apr; 63():9-16. PubMed ID: 22361659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
    Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
    Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
    Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
    Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
    Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
    Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
    Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
    Pestieau SR; Stuart OA; Sugarbaker PH
    Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC method for the pharmacokinetics and tissue distribution of taspine solution and taspine liposome after intravenous administrations to mice.
    Lu W; He LC; Zeng XM
    J Pharm Biomed Anal; 2008 Jan; 46(1):170-6. PubMed ID: 17889477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity.
    Foster BJ; Wiegand RA; Pugh S; LoRusso PM; Rake J; Corbett TH
    Clin Cancer Res; 1997 Nov; 3(11):2047-53. PubMed ID: 9815596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
    Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
    Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
    Abou El Hassan MA; Kedde MA; Zwiers UT; Tourn E; Haenen GR; Bast A; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):371-6. PubMed ID: 12898182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
    Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
    Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
    Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
    Schluep T; Cheng J; Khin KT; Davis ME
    Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.